AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Serologies in Connective Tissue Disease: What the Dermatologist Needs to Know

Description

In this presentation by Dr. Jeffrey Smith from Brigham Women's Hospital, he discusses the crucial serological tests relevant to connective tissue diseases for dermatologists. The talk begins with an overview of the initial serological evaluations for lupus, emphasizing the importance of the antinuclear antibody (ANA) test, specifically the gold standard method using indirect immunofluorescence on Hep-2 cells. Dr. Smith stresses the relationship between anti-double stranded DNA and disease activity in systemic lupus erythematosus (SLE) and highlights the use of anti-phospholipid antibodies in diagnosis. He also explores the significance of various autoantibodies related to conditions like dermatomyositis, including anti-synthetase syndrome, and notes specific antibody profiles that may indicate drug-induced lupus versus idiopathic lupus. The discussion covers serologies associated with systemic sclerosis, such as anti-SCL 70 and anti-centromere antibodies, while addressing the clinical implications of these tests for dermatological assessments and treatment considerations. Dr. Smith concludes by reviewing the prevalence and clinical associations of different autoantibodies, urging dermatologists to familiarize themselves with these markers for better patient management.

View more

Conclusions

  • The ANA (Antinuclear Antibody) test is the recommended gold standard for serological evaluation in connective tissue diseases, particularly in cutaneous lupus erythematosus.
  • Serum dilution affects the interpretation of ANA test results, with varying positivity rates in healthy individuals.
  • A high prevalence of ANA negative systemic lupus erythematosus (SLE) is rare and often associated with other autoantibodies.
  • In management of SLE, tracking anti-dsDNA and complement levels is more relevant than repeating ANA tests at every visit.
  • Certain autoantibodies, such as anti-Ro, are critical for evaluating the risk of neonatal lupus and associated cardiac complications in pregnant women with SLE.
  • Drug-induced lupus can present with unique serological profiles, necessitating a careful assessment of medication history to distinguish from idiopathic cases.
  • Autoantibody patterns can inform on disease severity and prognosis in patients with systemic sclerosis, with specific antibodies correlating with clinical outcomes.
  • Differing autoantibody profiles can help distinguish between dermatomyositis and related disorders.
  • It is unnecessary to conduct routine lab tests like ANA at every patient visit, focusing instead on the clinical context and specific symptomatic evaluations.
  • Garg, Merola, Fitzpatrick. Interdisciplinary approaches to Overlap Disorders in Dermatology and Rheumatology. Textbook. 2022.
  • Tan, E.M., Feltkamp, T.E.W., Smolen, J.S., Butcher, B., Dawkins, R., Fritzler, M.J., Gordon, T., Hardin, J.A., Kalden, J.R., Lahita, R.G. and Maini, R.N., 1997. Range of antinuclear antibodies in 'healthy' individuals. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 40(9), pp.1601-1611.
  • Lazar S, Kahlenberg JM. Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annual Review of Medicine. 2023 Jan 27;74:339-52.
  • Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum. 2010 Apr;62(4):1153-7.
  • Izmirly, P.M., Costedoat-Chalumeau, N., Pisoni, C.N., Khamashta, M.A., Kim, M.Y., Saxena, A., Friedman, D., Llanos, C., Piette, J.C. and Buyon, J.P., 2012. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation, 126(1), pp.76-82.
  • Waldman, R., DeWane, M.E. and Lu, J., 2020. Dermatomyositis: diagnosis and treatment. Journal of the American Academy of Dermatology, 82(2), pp.283-296.
  • Mecoli, C.A., Casal-Dominguez, M., Pak, K., Pinal-Fernandez, I., Albayda, J., Tiniakou, E., Paik, J.J., Zahid, U., Danoff, S.K., Mammen, A.L. and Casciola-Rosen, L., 2020. Myositis autoantibodies: a comparison of results from the Oklahoma Medical Research Foundation myositis panel to the Euroimmun research line blot. Arthritis & rheumatology (Hoboken, NJ), 72(1), p.192.
  • Nihtyanova, S.I. and Denton, C.P., 2010. Autoantibodies as predictive tools in systemic sclerosis. Nature reviews rheumatology, 6(2), pp.112-116.
  • Bennett et al. Journal of Cutaneous Pathology. 2023.
  • Stone, Caroline J., et al. "Overlapping clinical features in anti-synthetase syndrome and dermatomyositis: A case series." Journal of the American Academy of Dermatology 92.2 (2025): 313-315.